Advertisement

Topics

Ocular Therapeutix™ Announces Executive Transition Plans

16:05 EDT 22 Jun 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Antony Mattessich to Assume CEO Role in September 2017 and Joins Board; Amar Sawhney to Transition to Executive Chairman of the Board Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the develo...

Other Sources for this Article

Media
Medical Dynamics
Sandra Correa, 646-599-8637
Business & Media Group Director
scorrea@rxmedyn.com
or
Investors
Burns McClellan on behalf of Ocular Therapeutix
Steve Klass, 212-213-0006
sklass@burnsmc.com
or
Ocular Therapeutix
Scott Corning
Vice President of Marketing & Commercial Operations
scorning@ocutx.com

NEXT ARTICLE

More From BioPortfolio on "Ocular Therapeutix™ Announces Executive Transition Plans"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Novartis
Novartis is the fourth largest pharmaceutical company in the world, based on annual sales, which are exceeded $36,000m in 2009. Founded in 1996, Novartis focuses of four main areas; pharmaceuticals, vaccines & diagnostics, generic medicines and biosi...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...